Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases

NCT02681549 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT02681549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02681549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2016
Completion date
March 31, 2025
Enrollment
41 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastasis, melanoma, non-small cell lung cancer